The Europe Gabapentin Market should witness market growth of 4.0% CAGR during the forecast period (2022-2028).
A persistent brain disorder that is not contagious. It is characterized by recurring seizures, which are brief bursts of uncontrollable movement that can affect either a small portion of the bodyor the entire body. Approximately, 4-10 per 1000 people are thought to be affected by active epilepsy, which is defined as having ongoing seizures or requiring treatment at any given moment in the general population. Each year, epilepsy is thought to affect 5 million people. According to estimates, epilepsy affects 49 of every 100,000 people in high-income nations.
This number can reach 139 per 100,000 in underdevelopednations. This is probably caused by the increased risk of endemic diseases like neurocysticercosis or malaria, the increased frequency of birth-related injuries and injuries from motor vehicle accidents, as well as variations in the medical facilities, the provision of preventive health programs, and access to care. People with epilepsy comprise over 80% of the population in underdeveloped nations. As a result, epilepsy is one of the problems that are being treated with the use of gabapentin.
Sleep disorders are increasing in the region. Germany had a 4% prevalence of severe insomnia, lower than the 6-22% in other European nations. Most individuals have persistent symptoms, with many havingsignificant sleep issues for over a year. Severe insomniacs have higher rates of visits to family doctors, prescription drug use, diagnostic tests, and hospitalization. As a result, many regional governments have increased their healthcare expenditures to lessen the burden of health issues like insomnia and chronic pain. Hence, the requirement for drugs to treat sleep disorders, chronic pain, and other problems are increasing the demand for gabapentin, which is advancing the market's growth.
The Germany market dominated the Europe Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $168.8 million by 2028. The UK market is anticipated to grow at a CAGR of 3.1% during (2022-2028). Additionally, The France market would exhibit a CAGR of 4.8% during (2022-2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
A persistent brain disorder that is not contagious. It is characterized by recurring seizures, which are brief bursts of uncontrollable movement that can affect either a small portion of the bodyor the entire body. Approximately, 4-10 per 1000 people are thought to be affected by active epilepsy, which is defined as having ongoing seizures or requiring treatment at any given moment in the general population. Each year, epilepsy is thought to affect 5 million people. According to estimates, epilepsy affects 49 of every 100,000 people in high-income nations.
This number can reach 139 per 100,000 in underdevelopednations. This is probably caused by the increased risk of endemic diseases like neurocysticercosis or malaria, the increased frequency of birth-related injuries and injuries from motor vehicle accidents, as well as variations in the medical facilities, the provision of preventive health programs, and access to care. People with epilepsy comprise over 80% of the population in underdeveloped nations. As a result, epilepsy is one of the problems that are being treated with the use of gabapentin.
Sleep disorders are increasing in the region. Germany had a 4% prevalence of severe insomnia, lower than the 6-22% in other European nations. Most individuals have persistent symptoms, with many havingsignificant sleep issues for over a year. Severe insomniacs have higher rates of visits to family doctors, prescription drug use, diagnostic tests, and hospitalization. As a result, many regional governments have increased their healthcare expenditures to lessen the burden of health issues like insomnia and chronic pain. Hence, the requirement for drugs to treat sleep disorders, chronic pain, and other problems are increasing the demand for gabapentin, which is advancing the market's growth.
The Germany market dominated the Europe Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $168.8 million by 2028. The UK market is anticipated to grow at a CAGR of 3.1% during (2022-2028). Additionally, The France market would exhibit a CAGR of 4.8% during (2022-2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
Scope of the Study
By Application
- Epilepsy
- Restless Legs Syndrome
- Neuropathic Pain
- Others
By Dosage Form
- Capsule
- Tablet
- Oral Solution
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Zydus Lifesciences Ltd.
- Glenmark Pharmaceuticals Limited
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Alkem Laboratories Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Aurobindo Pharma Limited
- Amneal Pharmaceuticals, Inc.
- Cipla Limited
- Apotex, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Europe Gabapentin Market by Application
Chapter 4. Europe Gabapentin Market by Dosage Form
Chapter 5. Europe Gabapentin Market by Distribution Channel
Chapter 6. Europe Gabapentin Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Zydus Lifesciences Ltd.
- Glenmark Pharmaceuticals Limited
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Alkem Laboratories Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Aurobindo Pharma Limited
- Amneal Pharmaceuticals, Inc.
- Cipla Limited
- Apotex, Inc.
Methodology
LOADING...
Related Reports
Gabapentin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F
- Report
- 185 Pages
- Global
From
Gabapentin Market - Forecasts from 2024 to 2029
- Report
- 144 Pages
- Global
From
From
Gabapentin (CAS 60142-96-3) Global Market Research Report 2024
- Report
- 50 Pages
- Global
From
Gabapentin enacarbil (CAS 478296-72-9) Global Market Research Report 2024
- Report
- 50 Pages
- Global
From
About the Gabapentin Market
Gabapentin is a medication used to treat certain types of seizures and nerve pain. It is a central nervous system (CNS) drug, meaning it acts on the brain and spinal cord to produce its effects. It is used to treat epilepsy, neuropathic pain, hot flashes, and restless leg syndrome. It is also used off-label to treat anxiety and insomnia. Gabapentin is generally well-tolerated, but can cause side effects such as dizziness, drowsiness, and confusion. Gabapentin is available in both generic and Read more
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
